10-Q: Ultragenyx Reports Strong Revenue Growth, Pipeline Progress

Ultragenyx Pharmaceutical Inc. reported increased product sales and royalty revenue for the nine months ended September 30, 2025, alongside significant clinical advancements and a new $400 million royalty sale agreement.

Summary

• Total revenues for the nine months ended September 30, 2025, increased by 18% to $465.7 million, up from $395.4 million in the same period of 2024.
• Product sales grew by 25% to $267.3 million for the nine months ended September 30, 2025, compared to $213.5 million in 2024, driven by increased demand for Crysvita, Evkeeza, and Dojolvi.
• Crysvita product sales increased 22% to $136.8 million, Dojolvi sales increased 13% to $64.5 million, and Evkeeza sales surged 94% to $42.3 million for the nine months ended September 30, 2025.
• Crysvita royalty revenue increased 9% to $198.4 million for the nine months ended September 30, 2025.
• Net loss for the nine months ended September 30, 2025, was $(446.4) million, an increase from $(435.8) million in the prior year period.
• Research and development expenses increased by 7% to $546.7 million for the nine months ended September 30, 2025, primarily due to increased UX111 and UX143 manufacturing costs and GTX102 clinical progress.
• Selling, general and administrative expenses increased by 9% to $261.1 million for the nine months ended September 30, 2025, due to higher employee compensation and marketing expenses.
• Cash, cash equivalents, and marketable debt securities totaled $447.3 million as of September 30, 2025.
• The Phase 3 Orbit study for UX143 (Osteogenesis Imperfecta) is progressing to final analysis expected around the end of 2025, with an acceptable safety profile observed.
• Enrollment for the Phase 3 Aspire study of GTX-102 (Angelman Syndrome) is complete with 129 patients, and data is expected in the second half of 2026.
• The Phase 3 GlucoGene study for DTX401 (GSDIa) achieved its primary endpoint, showing a 61% mean reduction in daily cornstarch intake at Week 96, with a rolling BLA submission initiated in August 2025.
• Enrollment for the Phase 3 Enh3ance study of DTX301 (OTC deficiency) is complete with 37 patients.
• Enrollment for Cohort 4 of the pivotal Cyprus2+ study of UX701 (Wilson disease) is complete, with Stage 1 data expected in the first half of 2026.
• A Complete Response Letter (CRL) was received from the FDA for UX111 (MPS IIIA) in July 2025, citing CMC-related observations, with a BLA resubmission planned for early 2026.
• In November 2025, Ultragenyx entered into a new Royalty Purchase Agreement with OMERS for $400.0 million, granting OMERS an additional 25% of future Crysvita royalties in the U.S. and Canada, starting January 1, 2028, capped at $620.0 million.

Sentiment

Score: 6

Explanation: The company shows strong commercial growth and positive clinical advancements across multiple programs, particularly DTX401. However, the increased net loss, higher cash burn (prior to the OMERS deal), and the regulatory setback for UX111 temper the overall positive sentiment. The significant capital infusion from the OMERS royalty sale is a strong positive for liquidity.

Positives

• Total revenues increased by 18% to $465.7 million for the nine months ended September 30, 2025, demonstrating strong commercial performance.
• Product sales saw a significant 25% increase to $267.3 million, driven by key products like Evkeeza (94% growth), Crysvita (22% growth), and Dojolvi (13% growth).
• Crysvita royalty revenue increased by 9% to $198.4 million, indicating continued market penetration and patient reimbursement.
• The Phase 3 Orbit study for UX143 (Osteogenesis Imperfecta) is progressing well with an acceptable safety profile, nearing final analysis by year-end 2025.
• Enrollment for the Phase 3 Aspire study of GTX-102 (Angelman Syndrome) is complete, with data anticipated in the second half of 2026, marking a significant step forward for this program.
• DTX401 (GSDIa) Phase 3 GlucoGene study successfully met its primary endpoint, showing a clinically meaningful 61% reduction in daily cornstarch intake at Week 96, with glycemic control maintained.
• A rolling BLA submission for DTX401 began in August 2025 and is expected to complete in Q4 2025, indicating potential for regulatory approval soon.
• The company secured $400.0 million in November 2025 through a new royalty purchase agreement with OMERS, significantly bolstering liquidity.
• Management believes existing capital resources are sufficient to fund projected operating requirements for at least the next 12 months.

Negatives

• Net loss increased to $(446.4) million for the nine months ended September 30, 2025, compared to $(435.8) million in the prior year, indicating continued unprofitability.
• Cash, cash equivalents, and marketable debt securities decreased significantly to $447.3 million as of September 30, 2025, from $745.0 million at December 31, 2024, before the subsequent OMERS deal.
• Net cash used in operating activities increased to $(366.2) million for the nine months ended September 30, 2025, from $(334.7) million in the prior year, reflecting higher cash burn.
• Received a Complete Response Letter (CRL) from the FDA for UX111 (MPS IIIA) in July 2025, citing CMC-related observations, which will delay potential approval.
• Cost of sales increased by 33% for both the three and nine months ended September 30, 2025, outpacing revenue growth in some areas.
• Interest income decreased by 31% for the nine months ended September 30, 2025, primarily due to lower marketable debt securities balances.

Risks

• Continued operating losses are expected in the near term, and profitability by 2027 is based on assumptions that may materially differ from actual results.
• Limited experience in generating revenue from product sales, with success dependent on identifying rare disease patients and achieving significant market share.
• Need to raise additional capital to fund operations, complete clinical studies, and commercialize products, with no guarantee of availability on acceptable terms.
• Clinical drug development is lengthy, complex, expensive, and unpredictable, with potential for substantial delays and uncertain outcomes, including failures in later-stage studies.
• Difficulty in enrolling patients for clinical studies due to the rarity of target diseases and specific eligibility criteria, potentially delaying or preventing study completion.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with no guarantee of approval even with positive clinical results.
• Fast Track, Breakthrough Therapy, Priority Review, or RMAT designations do not guarantee faster development or approval, nor do they increase the likelihood of marketing approval.
• Product candidates may cause undesirable side effects, leading to clinical study delays, more restrictive labels, or denial/withdrawal of regulatory approval.
• Gene therapy products are novel, complex, expensive, and difficult to manufacture, posing risks of production interruptions, quality issues, and supply limitations.
• Products are subject to ongoing regulatory scrutiny even after approval, with potential for sanctions, fines, or withdrawal of approval if compliance is not maintained.
• Product liability lawsuits could result in substantial liabilities, exceeding insurance coverage, and limit commercialization efforts.
• Dependence on Kyowa Kirin Co., Ltd. (KKC) for commercialization of Crysvita in major markets (U.S. and Canada) and for product supply, with KKC having no obligation to use diligent efforts.
• Reliance on third parties for manufacturing products and product candidates, with risks of supply interruptions, increased costs, and non-compliance with regulatory requirements.
• Drug substance and drug product for most products and candidates are from single-source suppliers, and loss of these suppliers could materially affect the business.
• Market opportunities for products and product candidates may be smaller than estimated, impacting revenue generation and profitability.
• Intense competition and rapid technological change, including AI, from competitors with greater resources, could adversely affect financial condition and commercialization efforts.
• Inability to effectively manage organizational expansion, including building an integrated commercial organization, could lead to operational mistakes and reduced productivity.
• Commercial success depends on market acceptance by physicians, patients, and payors, which is uncertain even with regulatory approvals.
• Uncertainty regarding insurance coverage and reimbursement status of newly approved products, potentially limiting market access and revenue generation.
• Inability to obtain and maintain effective patent rights or facing claims of intellectual property infringement could prevent or delay development and commercialization.
• Changes to patent laws in the U.S. and other jurisdictions could diminish the value of patents, impairing protection for products.
• Limited experience operating its own manufacturing facility (Bedford, Massachusetts gene therapy facility) may lead to unexpected costs or challenges, including regulatory approval for manufacturing processes.
• Dependence on key personnel, including the Founder, President, and CEO, with loss of services potentially impacting objectives.
• Inability to obtain or maintain orphan drug exclusivity could lead to competition and reduced revenue.
• Operating results could be adversely impacted if intangible assets become impaired.
• Failure to identify, license, discover, develop, or commercialize additional product candidates could materially affect the business.
• Non-compliance with evolving healthcare laws, regulations, and policies, including fraud and abuse laws and privacy regulations, could result in significant penalties.
• International expansion exposes the company to business, regulatory, political, operational, financial, and economic risks, including foreign currency fluctuations and trade tensions.
• Risk of employee or consultant misconduct, including non-compliance with regulatory standards or improper use of information, leading to significant liability and reputational harm.
• Promotion of off-label uses could lead to significant liability from regulatory agencies.
• Computer system failures or security breaches could result in loss of data, intellectual property, or disruption of operations.
• Adverse effects from earthquakes or other natural disasters, particularly in the San Francisco Bay Area and Japan, where key operations and partners are located.
• Acquisitions or strategic transactions could divert management attention, incur costs, and result in fluctuations in investment value.
• The market price of common stock is highly volatile and subject to various factors, including clinical results, regulatory decisions, and macroeconomic conditions.
• Future sales and issuances of common stock could dilute existing stockholders and cause stock price to fall.
• Provisions in corporate documents and Delaware law could make it more difficult for a third party to acquire the company or remove current management.
• Inability to maintain effective internal control over financial reporting could lead to loss of investor confidence and stock price decrease.
• Potential for additional tax liabilities due to multinational tax structure and disagreements with taxing authorities.
• Limitations on the ability to use net operating loss carryforwards and other tax attributes.
• Litigation, including patent infringement suits and other claims, could substantially increase costs and harm the business.
• Increased scrutiny regarding ESG practices and disclosures could result in additional costs and adversely impact business and reputation.

Future Outlook

The company expects to continue incurring annual operating losses in the near term but anticipates achieving profitability for the year 2027, based on various assumptions. Research and development expenses are expected to moderate in the future as product candidates advance. Selling, general and administrative expenses are projected to increase to support existing approved products, multiple clinical-stage candidates, and planned product launches. The company believes its existing capital resources are sufficient to fund projected operating requirements for at least the next 12 months.

Management Comments

• Our strategy is predicated upon timeand cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
• We have had constructive formal and informal discussions with the FDA and currently plan to resubmit the BLA for UX111 in early 2026.
• We expect our annual research and development expenses to moderate in the future as we advance our product candidates through clinical development.
• We expect annual selling, general and administrative expenses to increase in the future as we continue to support our existing approved products, multiple clinical-stage product candidates, and planned launches of additional products.
• We believe that our existing capital resources will be sufficient to fund our projected operating requirements for at least the next 12 months.

Industry Context

Ultragenyx operates in the highly specialized and competitive biopharmaceutical industry, focusing on rare and ultra-rare genetic diseases. The company's pipeline includes biologics, small molecules, AAV gene therapy, and nucleic acid product candidates, reflecting a diversified approach within the rare disease space. The gene therapy segment, while promising, faces evolving regulatory frameworks and manufacturing complexities, as evidenced by the UX111 CRL. The industry continues to see significant investment in novel therapies, but also faces increasing scrutiny on drug pricing and reimbursement, as well as macroeconomic pressures. The company's strategy of leveraging collaborations and royalty sales for funding is a common practice in the capital-intensive biotech sector.

Comparison to Industry Standards

• The 94% growth in Evkeeza product sales for the nine months ended September 30, 2025, is a strong performance, potentially outpacing many new rare disease product launches, though specific comparable company data is not provided in the filing.
• The 61% reduction in daily cornstarch intake for DTX401 in GSDIa patients at Week 96 is a significant clinical outcome, suggesting a strong efficacy profile for a rare metabolic disorder, which could be competitive against existing or emerging therapies for similar conditions.
• The receipt of a Complete Response Letter (CRL) for UX111 due to CMC issues is a common challenge in the gene therapy sector, where manufacturing processes are complex and regulatory standards are stringent. This is not unique to Ultragenyx, as other gene therapy developers have faced similar manufacturing-related delays (e.g., bluebird bio, Sarepta Therapeutics).
• The company's reliance on royalty sales (RPI, OMERS) for capital is a recognized financing strategy in the biotech industry, allowing companies to monetize future revenue streams without equity dilution, similar to deals seen with Royalty Pharma or other specialized royalty funds.

Legal Proceedings

• Ultragenyx Pharmaceutical Inc. and Baylor Research Institute v. Navinta LLC, Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Esjay Pharma Private Limited and Esjay Pharma LLC: A patent infringement suit filed on September 26, 2024, under the Hatch-Waxman Act against generic manufacturers seeking FDA approval for a generic version of Dojolvi. The suit triggers a stay preventing FDA approval until December 30, 2027. Discovery is ongoing.
• Ultragenyx Pharmaceutical Inc. v. Catalent Maryland, Inc. and Catalent Pharma Solutions LLC: A suit filed on October 9, 2024, alleging fraudulent misrepresentation of manufacturing capabilities and breach of manufacturing agreement, seeking monetary damages in excess of $100 million. Catalent filed motions to dismiss, which Ultragenyx opposed.

Related Party Transactions

• An agreement with a non-profit foundation, where two Ultragenyx board members (including the CEO) also served as board members, for an aggregate $1.0 million contribution over a four-year period (beginning Q3 2022) to support rare disease education and awareness. $0.3 million was recorded as research and development expense for the three and nine months ended September 30, 2025 and 2024, respectively. No further obligations under this agreement.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from pipeline advancements and revenue growth, but also exposure to increased net losses, cash burn, and regulatory delays (UX111 CRL). The recent $400 million royalty sale provides liquidity but monetizes future revenue.
• Patients: Continued progress in clinical trials for rare diseases (OI, Angelman Syndrome, GSDIa, OTC deficiency, Wilson disease) offers hope for new treatment options. The UX111 CRL represents a delay for Sanfilippo syndrome type A patients.
• Employees: Increased selling, general and administrative expenses suggest continued investment in personnel, but the company's history of operating losses and need for additional capital could pose long-term stability concerns if profitability is not achieved.
• Customers (distributors/specialty pharmacies): Increased product sales indicate strong demand for existing products, but reliance on a limited number of distributors creates concentration risk.
• Creditors: The company's ability to fund operations relies on existing capital, revenue, and future financing, including royalty sales, which impacts its credit profile.

Next Steps

• Complete final analysis for the Phase 3 Orbit study of UX143 around the end of 2025.
• Evaluate patients in the Cosmic study for UX143 in parallel with the final Orbit analysis around the end of 2025.
• Resubmit the Biologics License Application (BLA) for UX111 in early 2026, followed by an FDA review period of up to six months.
• Complete the rolling BLA submission for DTX401 in the fourth quarter of 2025.
• Unblind the Phase 3 Enh3ance study for DTX301 after Week 36 to measure changes in 24-hour plasma ammonia levels.
• Follow patients in the DTX301 Enh3ance study for a total of up to 64 weeks to determine complete responders.
• Expect Stage 1 data from the pivotal Cyprus2+ study of UX701 in the first half of 2026.
• Continue to support existing approved products and multiple clinical-stage product candidates.
• Plan for future product launches, which will lead to increased selling, general and administrative expenses.
• Vigorously defend intellectual property in the patent infringement suit against Navinta, Aurobindo, and Esjay regarding generic Dojolvi.
• Continue litigation against Catalent for alleged fraudulent misrepresentation and breach of manufacturing agreement.

Key Dates

Recommendation

Ultragenyx demonstrates strong commercial momentum with significant revenue growth across its approved products and promising clinical progress for several pipeline candidates, notably DTX401's positive Phase 3 data and BLA submission. The recent $400 million royalty sale provides a substantial boost to liquidity, extending the financial runway. However, the company continues to incur significant net losses and cash burn, and the Complete Response Letter for UX111 introduces a notable delay and uncertainty for a key gene therapy program. While the long-term potential in rare diseases remains attractive, these mixed signals warrant a 'hold' recommendation, suggesting investors monitor the resolution of the UX111 CRL, the progress of other late-stage programs, and the path to profitability before making further investment decisions.

Keywords

Rare Disease, Gene Therapy, Biopharmaceutical, Orphan Drug, Crysvita, Dojolvi, Evkeeza, Mepsevii, UX143, GTX-102, UX111, DTX401, DTX301, UX701, X-Linked Hypophosphatemia, XLH, Mucopolysaccharidosis VII, MPS VII, Long-chain Fatty Acid Oxidation Disorders, LC-FAOD, Homozygous Familial Hypercholesterolemia, HoFH, Osteogenesis Imperfecta, OI, Angelman Syndrome, Sanfilippo Syndrome Type A, MPS IIIA, Glycogen Storage Disease Type Ia, GSDIa, Ornithine Transcarbamylase Deficiency, OTC Deficiency, Wilson Disease, SEC Filing, 10-Q, Clinical Trials, Regulatory Approval, FDA, EMA, Royalty Pharma, OMERS, Biologics License Application, BLA, Complete Response Letter, CMC, Financial Results